EN DE
Watch Sedana Medical AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sedana Medical AB (SEDANA) fair value: what the stock is really worth

As of Nov 12, 2026: fair value (intrinsic value) of Sedana Medical AB stock SEK 8.47, price SEK 9.00, that is 5.9% below the price, quality 43 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0015988373

SM Sedana Medical AB logo Thin data Nov 10, 2026

Sedana Medical AB

SEDANA · ST

The stock is already about fairly priced, weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value kr 8.47 · Fairly valued 
Quality 43/100 
Price moving sideways (no uptrend) 
Expensive Growth (revenue 5y +7.1 %/yr in SEK) 
Loss-making · -17.4% net margin (TTM) 
Negative free cash flow 
Trails peers (3/10) 
Narrow moat 15/100 · thin data
Thin data 
Estimate
Watch Sedana Medical AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 107.10 kr 6.88 Fair Value kr 8.47 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 6.88 – kr 107.10 · fair‑value band kr 6.35 – kr 10.59 · the kr 9.00 price screens above the kr 8.47 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Sedana Medical in your weekly email

Every Wednesday you see whether Sedana Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sedana Medical AB (publ), a medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Spain, Germany, and internationally.

Show moreShow less

The company offers Sedaconda ACD-L and Sedaconda ACD-S, which are disposable medical devices that enable the administration of volatile anaesthetics; Sedaconda Syringe, a syringe with a connection to fit the connector on the agent line of the Sedaconda ACD and Sedana Medical filling adapters; Sedaconda ACD starter kit; Sedaconda (Isoflurane) for maintenance of sedation in intubated or tracheostomised mechanically ventilated adult and paediatric patients from 3 years of age; Sedaconda Filling Adapter, a single-use medical device; FlurAbsorb Pro-L and Pro-S; FlurAbsorb and Mounts; Scavenging Tube, a one piece pre-connected tube, that is designed to channel anaesthetic waste gas from the ventilator exhaust port and the gas monitor exhaust port to the FlurAbsorb filter; and Mindray exhaust connector enables to connect the exhaust of the ventilator to an active or passive scavenging system.

The company was founded in 1999 and is headquartered in Danderyd, Sweden.

Stock analysis

Sedana Medical AB (SEDANA) currently trades at kr 9.00, while our estimate is kr 8.47, so the stock looks roughly fairly valued today (gap 6.3%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 6.35 (bear) to kr 10.59 (bull), the price of kr 9.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Sedana Medical AB reported revenue of 200M SEK in FY2025 versus 159M SEK in FY2021, a compound +5.9%/yr. Reported net income was −59.2M SEK in FY2025.

Key figures

Market cap 979M SEK (≈ $97.7M) Micro · P/S ratio 4.94 · EPS (TTM) kr −0.3500 · Net margin −17.4% · Return on equity −3.9% · Return on assets (EBIT) −5.9% (5-year average) · Operating margin −30.0% · Revenue (TTM) 198M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).

What moves the price

The share trades about 34% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 9% fair-value upside, at −6%, SEDANA screens richer than that median.

Fair Value

Bear kr 6.35 Fair Value kr 8.47 Bull kr 10.59
Price kr 9.00 · Downside -5.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 41
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 45
How calm the share price moves, does not count
Price momentum 30
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 21
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 22/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+12.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Start year 2020 (pandemic). Over 10 years: +21.7% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−15.2% (2020) → −16.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch SEDANA, get fair value alerts →

Compare Sedana Medical AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 404 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside −5.9% · Above median
Profitability
Return on assets −6.2% · Below median
Net margin (12 months) −17.4% · Below median
Operating margin (12 months) −30.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 7.2% · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.09× · Cheapest 25%
P/S (12 months) 4.94× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)25 · sector 15
FUTURE (revenue growth)36 · sector 43
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥177.51 ¥202.57 +14% vs SEDANA
Boston Scientific Corporation BSX $44.20 $49.64 +12% vs SEDANA
STERIS plc STE $253.44 $281.90 +11% vs SEDANA
Stryker Corporation SYK $312.39 $343.63 +10% vs SEDANA
DexCom, Inc DXCM $81.39 $88.38 +9% vs SEDANA
GE HealthCare Technologies Inc GEHC $81.84 $69.92 −15% vs SEDANA
Edwards Lifesciences Corporation EW $105.80 $81.94 −23% vs SEDANA
Medtronic plc MDT $100.99 $74.90 −26% vs SEDANA
Abbott Laboratories, ABT $107.25 $75.28 −30% vs SEDANA
Koninklijke Philips N.V PHIA €27.26 €15.23 −44% vs SEDANA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sedana Medical AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sedana Medical AB Fair Value". https://www.fairvalue-calculator.com/stock/SEDANA

Frequently asked questions

Is Sedana Medical AB (SEDANA) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 8.47 versus a price of kr 9.00, about 6% lower (fairly valued).
What is the fair value of SEDANA?
Our estimate for Sedana Medical AB is kr 8.47 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 9.00.
What is the quality score of SEDANA?
Sedana Medical AB has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sedana Medical AB (SEDANA)?
Our calculated price target is the estimate of kr 8.47 (as of Nov 10, 2026). Cautious scenario kr 6.35, optimistic scenario kr 10.59. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Sedana Medical AB stock forecast for 2026?
Our estimate puts fair value at kr 8.47, about 6% lower versus a price of kr 9.00 (fairly valued). Cautious scenario kr 6.35, optimistic scenario kr 10.59. The calculation is refreshed regularly with new filings.
What is the revenue of Sedana Medical AB (SEDANA)?
Sedana Medical AB reported trailing-twelve-month revenue of about 198M SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Sedana Medical AB (SEDANA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sedana Medical AB it is kr 8.47 per share (as of Nov 10, 2026), against a price of kr 9.00.
Is Sedana Medical AB stock overvalued or undervalued in 2026?
As of Nov 10, 2026, SEDANA trades above its calculated fair value: price kr 9.00, fair value kr 8.47, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SEDANA?
No. The price is what the market pays today (kr 9.00); the fair value is what the company's own numbers justify (kr 8.47). For Sedana Medical AB the two are kr 0.5300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sedana Medical AB worth?
The market values Sedana Medical AB at about 979M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 9.00; our models calculate a fair value of kr 8.47 per share.
What do the bullish and bearish scenarios say about SEDANA?
Our models span a range for Sedana Medical AB: cautious scenario kr 6.35, base kr 8.47, optimistic kr 10.59 per share (as of Nov 10, 2026, price kr 9.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sedana Medical AB (SEDANA)?
Balance-sheet figures for Sedana Medical AB (as of Nov 10, 2026): return on equity −3.9%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is SEDANA from its 52-week high?
Sedana Medical AB trades at kr 9.00, about 34% below its 52-week high of kr 13.62 and 13% above the low of kr 7.93 (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of kr 8.47 is for.
Which stocks are comparable to Sedana Medical AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sedana Medical AB stock attractive at the current price?
The data as of Nov 10, 2026: price kr 9.00, calculated fair value kr 8.47 (−6%), Quality Score 43/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. Sedana Medical AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sedana Medical AB (SEDANA)?
The closing price on Nov 12, 2026 was kr 9.00. Our estimate is kr 8.47, about 6% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sedana Medical AB right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Sedana Medical AB

How large is the market capitalisation of Sedana Medical AB (SEDANA)?
The market capitalisation of Sedana Medical AB is 979M SEK (≈ $97.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sedana Medical AB (SEDANA)?
The price-to-sales ratio of Sedana Medical AB is 4.94 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sedana Medical AB (SEDANA)?
Earnings per share at Sedana Medical AB are kr −0.3500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sedana Medical AB (SEDANA)?
The net margin of Sedana Medical AB is −17.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sedana Medical AB (SEDANA)?
The return on equity (ROE) of Sedana Medical AB is −3.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sedana Medical AB (SEDANA)?
On an EBIT basis the return on assets of Sedana Medical AB is −5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sedana Medical AB (SEDANA)?
The operating margin of Sedana Medical AB is −30.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sedana Medical AB (SEDANA)?
Revenue at Sedana Medical AB is growing +7.2% versus a year earlier (3y avg +17.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sedana Medical AB (SEDANA) generate?
The free cash flow of Sedana Medical AB is −75.2M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sedana Medical AB (SEDANA) hold?
Sedana Medical AB holds more cash than debt, 86.3M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sedana Medical AB in the live analysis

One click puts Sedana Medical AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.